Prevalence of Metabolic Syndrome Associated with Body Burden Levels of Dioxin and Related Compounds among Japan’s General Population

Hirokazu Uemura, 1, Kokichi Arisawa, 1, 2 Mineyoshi Hiyoshi, 1 Atsushi Kitayama, 1 Hidenobu Takami, 1 Fusakazu Sawachika, 1 Satoru Dakeshita, 1 Kentaro Nii, 1 Hiroshi Satoh, 2 Yoshio Sumiyoshi, 2 Kenji Morinaga, 2 Kazunori Kodama, 2 Taka-ichiro Suzuki, 2 Masaki Nagaï, 2 and Tsuguyoshi Suzuki 2 *

1 Department of Preventive Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan; 2 Study Group on the Accumulation of Dioxins in Humans, Tokyo, Japan

BACKGROUND: Environmental exposure to some persistent organic pollutants has been reported to be associated with a metabolic syndrome in the U.S. population.

OBJECTIVES: We evaluated the associations of body burden levels of dioxins and related compounds with the prevalence of metabolic syndrome among the general population in Japan.

METHODS: We conducted a cross-sectional study during 2002–2006. In fasting blood samples, we measured biochemical factors and determined lipid-adjusted concentrations of 10 polychlorinated dibenzo-p-dioxins (PCDDs), 7 polychlorinated dibenzofurans (PCDFs), and 12 dioxin-like polychlorinated biphenyls (DL-PCBs) all of which have toxic equivalency factors. We also performed a questionnaire survey.

RESULTS: The toxic equivalents (TEQs) of PCDDs, PCDFs, and DL-PCBs and total TEQs had significant adjusted associations with metabolic syndrome, whether or not we excluded diabetic subjects. By analyzing each component of metabolic syndrome separately, the DL-PCB TEQs and total TEQs were associated with all components, and the odds ratios (ORs) in the highest quartile of DL-PCB TEQs in four of the five components were higher than those for PCDDs or PCDFs. We also found congener-specific associations with metabolic syndrome; in particular, the highest quartiles of PCB-126 and PCB-105 had adjusted ORs of 9.1 and 7.3, respectively.

CONCLUSIONS: These results suggest that body burden levels of dioxins and related compounds, particularly those of DL-PCBs, are associated with metabolic syndrome. Of the components, high blood pressure, elevated triglycerides, and glucose intolerance were most closely associated with these pollutants.

KEY WORDS: cross-sectional study, metabolic syndrome, dioxins, PCBs, PCDDs, PCDFs, polychlorinated biphenyls, polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans. Environment Health Perspect 117:568–573 (2009). doi:10.1289/ehp.0800012 available via http://dx.doi.org/ [Online 10 October 2008]

Polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs), collectively called dioxins, are produced through the burning of garbage and some types of chemical manufacturing processes. Legal regulations of dioxins in the 1990s in Japan have achieved a 95% reduction in their emissions from incinerators (Ministry of the Environment, Government of Japan 2004). Some forms of polychlorinated biphenyls (PCBs), which are persistent organic pollutants (POPs), exhibit toxic actions similar to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and are called dioxin-like PCBs (DL-PCBs). PCDDs/PCDFs and DL-PCBs are widely persistent in the environment because they are lipophilic and resistant to biological and chemical degradation. Several congeners of these pollutants exhibit various biological and toxic actions, such as dermal toxicity, immunotoxicity, carcinogenicity, and adverse effects on reproductive, neurobehavioral, and endocrine functions (Lindström et al. 1995; Weisglas-Kuperus 1998). Johnson et al. (2001) and Lee et al. (2006) have suggested that these actions could be induced by low-level exposure to these pollutants.

Metabolic syndrome, characterized by a cluster of metabolic disorders including central obesity, glucose intolerance, dyslipidemia, and hypertension, has been increasing in developed countries (Flegal et al. 2002; Ford 2005). The health impact of each component of the metabolic syndrome may be small, but the occurrence of several components may have considerably greater impact than any one alone (Nakanishi et al. 2003). Subjects suffering from metabolic syndrome may be at increased risk of type 2 diabetes (Lorenzo et al. 2003; Sattar et al. 2003) and cardiovascular diseases (Lakka et al. 2002; Malik et al. 2004; McNeill et al. 2005). Recently, background environmental exposure to some POPs has been reported to be associated with increased risk of diabetes (Lee et al. 2006) and with increased risk of metabolic syndrome (Lee et al. 2007) in the U.S. population in the 1999–2002 National Health and Nutrition Examination Survey (NHANES). Metabolic syndrome has become widely prevalent in the populations in Asian countries, including Japan, but whether similar associations exist among Asian populations has not been evaluated. A survey on the accumulation of dioxins and related compounds in humans was carried out beginning in 2002 under the supervision of the Ministry of the Environment, Government of Japan. In this article, we report the recent 5-year results of a cross-sectional study to evaluate the associations of body burden levels of PCDDs, PCDFs, and DL-PCBs with the prevalence of metabolic syndrome, and with the prevalence of its components, among general inhabitants in Japan.

Materials and Methods

Survey areas and participants. We conducted this survey from 2002 to 2006 in Japan on 1,374 participants (627 male and 747 female) 15–73 years of age. The selection of survey areas and the recruitment of the participants have been reported previously (Uemura et al. 2008). Briefly, we divided the whole of Japan into five regional blocks (Table 1) and selected a single prefecture from each regional block every year. We recruited approximately 50 individuals in each prefecture; approximately 20 were from urban areas, 15 from farming village areas, and 15 from fishing village areas, with almost equal distribution of age and sex among the three areas. As a whole, we performed this study under the supervision of the Ministry of the Environment, Government of Japan. We thank T. Kitamado and M. Hasegawa (Ministry of the Environment, Government of Japan) and M. Hijiya and Y. Chisaki (IDEA Consultants, Inc.) for their cooperation and encouragement during the study. We also thank members of the committee of the “Accumulation of Dioxins in Humans”; I. Uchiyam (Graduate School of Engineering, Kyoto University), F. Kayama (Jichi Medical University), H. Saito (Nagasaki University), N. Suzuki (National Institute for Environment Studies), T. Sobue (National Cancer Center Research Institute), S. Tominaga (Aichi Health Promotion Foundation), H. Miyata (Faculty of Pharmaceutical Science, Setsunan University), M. Morita (National Institute for Environmental Studies/Ehime University), C. Tohyama (Center for Disease Biology and Integrative Medicine, University of Tokyo), and S. Watanabe (National Institute of Health and Nutrition). The authors declare they have no competing financial interests.

Received 18 July 2008; accepted 10 October 2008.
the subjects participated from 75 different residential areas of 25 prefectures through 5 survey years and were evenly distributed in age and sex among the urban, farming, and fishing village areas in each survey year. Participants were required to have been living in the same area for at least 10 years, to have had no known occupational exposure to PCDDs/PCDFs and DL-PCBs, and to have no known severe anemia or other health problems that interfere with blood sampling. Participation in this study was essentially voluntary, and after we explained the details of this survey, we obtained written informed consent from each participant. We designed the study to recruit at least 250 participants every survey year; few subjects were excluded because of known severe anemia or other health problems during the survey years. The study protocol was reviewed and approved by the Ethical Committee of the Ministry of the Environment, Government of Japan.

**Questionnaire.** We asked participants to complete a questionnaire to obtain data on individual characteristics, including body height and weight, residential and occupational histories, smoking and drinking habits, and past history of diseases and treatments. Regarding drinking habits, subjects were asked how often they had consumed beer, sake, shochu (rough distilled spirits), and whisky over the previous month. The frequency of each item in the questionnaire was classified into five categories: almost everyday (6 times/week), 3–4 times/week (3.5/week), 1–2 times/week (1.5/week), 1–2 times/month (0.35/week), and almost never (0.1/week). We did not specify the unit or portion of each item. The frequency of alcohol consumption was summarized as the sum of the frequency of each item and then divided into three categories: regular, ≥ 6 times/week; often, 1.5 to < 6 times/week; rarely or never, < 1.5 times/week.

**Measurements.** We obtained approximately 25 mL fasting venous blood from each participant, with 20 mL collected into Vacutainer tubes containing sodium heparin (VT-100H, Terumo, Tokyo, Japan; or 367677, Becton Dickinson and Company, Tokyo, Japan). PCDDs, PCDFs, and DL-PCBs were analyzed in whole blood at the Institute of General Science for the Environment, METOCEAN Environment (currently IDEA Consultants, Inc., Shizuoka, Japan) by isotope dilution high-resolution gas chromatography/mass spectrometry, after liquid/liquid extraction and gel cleanup. The detailed analytical procedure of these chemicals has been previously reported (Nakamura et al. 2008). Percent blood lipid was measured gravimetrically using a sulfuric ammonium-ethanol/hexane technique. Concentrations of 7 PCDD congeners, 10 PCDF congeners, and 12 DL-PCB congeners that have toxic equivalency factors (TEFs).

The limit of detection (LOD) was 1 pg/g lipid for PCDDs/PCDFs with four or five chlorine atoms, 2 pg/g lipid for PCDDs/PCDFs with six or seven chlorine atoms, 4 pg/g lipid for PCDDs/PCDFs with eight chlorine atoms, and 10 pg/g lipid for DL-PCBs.

We calculated toxic equivalents (TEQs) using the 1998 World Health Organization TEF (Van den Berg et al. 1998). We assigned zero concentrations to pollutant levels < LOD.

We determined high-density lipoprotein (HDL) cholesterol, triglycerides, and hemoglobin A1c (HbA1c) in the blood with an automatic biochemical analyzer (model 7450; Hitachi, Tokyo, Japan).

Blood pressure was measured in each subject sitting at rest. If a measurement was extremely high or low or far from everyday values, we tried again after a short rest and used the second measurement as the final measurement.

**Assessment of metabolic syndrome.** We assessed the prevalence of metabolic syndrome using a modification of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) definition (NCEP 2002). Some studies in Asia have suggested that the criteria of central obesity proposed by the NCEP, which is based on the data from Caucasians, is inappropriate for Asian populations, whose builds are generally smaller than those of Caucasians (Ko et al. 2005; Tan et al. 2004). Therefore, we diagnosed subjects with metabolic syndrome when they satisfied three or more of the following five criteria: a) body mass index (BMI) ≥ 25 kg/m² (rather than by abdominal waist circumference); b) serum triglycerides ≥ 150 mg/dL; c) serum HDL < 40 mg/dL in men or < 50 mg/dL in women; d) systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85 mmHg, or self-reported history of physician-diagnosed hypertension; e) HbA1c ≥ 5.6% (rather than fasting serum glucose), or self-reported history of physician-diagnosed diabetes.

The association of diabetes mellitus with PCBs and other POPs is well established, and diabetes mellitus is a partial component of metabolic syndrome. Therefore, we further investigated the associations of these pollutants with metabolic syndrome in the absence of diabetes mellitus by excluding subjects who either self-reported a history of physician-diagnosed diabetes or had plasma HbA1c > 6.1%. This HbA1c level predicts fasting plasma glucose ≥ 126 mg/dL, the standard for determining diabetes, with a sensitivity of 63.2% and a specificity of 97.4% (Rohlfing et al. 2000).

**Statistical analysis.** We evaluated the sex difference of BMIs by the Wilcoxon rank-sum test. We analyzed the associations of the TEQs of PCDDs, PCDFs, DL-PCBs, and total TEQs with the prevalence of metabolic syndrome by excluding or including prevalent diabetes in logistic regressions, nonadjusted and adjusted for age, sex, smoking and drinking habits, regional block, residential area, and survey year. We tested the adjusted associations of the TEQs with the five components of metabolic syndrome in logistic regressions. We also evaluated separately the adjusted associations of the concentrations of the 16 selected congeners for which > 75% of the subjects had concentrations > LOD with the prevalence of metabolic syndrome in logistic regressions: 1,2,3,7,8-penta (Pe) CDD, 1,2,3,6,7,8-hexa (Hx) CDD, 1,2,3,4,6,7,8-hepta (Hp) CDD, octaCDD (OCDD), 2,3,4,7,8-PeCDF, 1,2,3,6,7,8-HxCDF, PCB-126, PCB-169, PCB-185, PCB-114, PCB-123, PCB-156, PCB-157, PCB-167, and PCB-189. In these analyses, we defined the first quartile (< 25th percentile) as the reference; created dummy variables for sex, regional block, residential area, survey year, smoking habit, and drinking habit; and included all except reference categories in the model. We conducted tests of trend using the median value for each quartile of the TEQs or the concentrations of the congeners in logistic models. All statistical analyses were performed using SAS software (version 8.2; SAS Institute Inc., Cary, NC, USA). All p-values are two-tailed, and we considered those < 0.05 statistically significant.

| Table 1. Baseline characteristics (%) of the participants. |
|------------------------------------------------------------|
| Both sexes | Male | Female |
| Age [years] | | | |
| 15–29 | 20.7 | 22.7 | 19.0 |
| 30–39 | 18.7 | 20.6 | 17.1 |
| 40–49 | 21.9 | 20.3 | 23.3 |
| 50–59 | 24.0 | 23.3 | 24.6 |
| 60–73 | 14.7 | 13.2 | 15.9 |
| Regional block | | | |
| Hokkaido/Tokushu | 19.9 | 19.1 | 20.5 |
| Kanto/Koshin’etsu | 20.0 | 17.2 | 22.4 |
| Tohoku/Hokuriku/Kinki | 20.5 | 24.4 | 17.3 |
| Chugoku/Shikoku | 19.3 | 21.2 | 17.7 |
| Kyushu/Okinawa | 20.3 | 18.0 | 22.2 |
| Residential area | | | |
| Urban | 40.2 | 37.6 | 42.3 |
| Farming village | 32.0 | 33.0 | 31.2 |
| Fishing village | 27.8 | 29.4 | 26.5 |
| Survey year | | | |
| 2002 | 18.9 | 18.7 | 19.0 |
| 2003 | 19.8 | 19.6 | 20.0 |
| 2004 | 19.2 | 17.9 | 20.4 |
| 2005 | 21.0 | 21.5 | 20.5 |
| 2006 | 21.2 | 22.3 | 20.2 |
| Smoking habit | | | |
| Current | 21.8 | 40.2 | 6.3 |
| Past | 13.1 | 22.0 | 5.6 |
| Never | 64.8 | 37.5 | 87.4 |
| Unknown | 0.5 | 0.3 | 0.7 |
| Drinking habit | | | |
| Regular | 20.7 | 36.8 | 7.1 |
| Often | 22.3 | 27.3 | 18.2 |
| Rarely or never | 53.7 | 32.7 | 71.4 |
| Unknown | 3.3 | 3.2 | 3.3 |
Table 5 lists the nonadjusted and adjusted associations of the TEQs with the prevalence of metabolic syndrome, including the subjects with prevalent diabetes. Among the 65 diabetic subjects, we diagnosed 38 subjects with metabolic syndrome. When we excluded prevalent diabetes from the analyses, we defined 122 subjects as having metabolic syndrome. The adjusted associations of the TEQs of DL-PCBs with metabolic syndrome were strengthened, whereas those of PCDDs were slightly attenuated (p for trend = 0.07).

The adjusted associations of the TEQs with the prevalence of each component of metabolic syndrome are shown in Table 6. All of the TEQs of PCDDs, PCDFs, and DL-PCBs and total TEQs were associated with high blood pressure and elevated triacylglycerides (tests of trend were all significant). The TEQs of PCDDs and DL-PCBs and total TEQs showed trends for the associations with high HbA1c (p for trends all < 0.01). In particular, the highest quartiles of DL-PCBs and total TEQs had adjusted ORs of 8.0 and 8.6, respectively, in the prevalence of high HbA1c. Of note, the TEQ of DL-PCBs as well as total TEQs showed trends for the associations with all five components of metabolic syndrome, and the ORs in the highest quartile of the TEQ of DL-PCBs in four of the five components were higher than those for PCDDs or PCDFs. In contrast, the TEQs of PCDFs were not associated with high BMI (p for trend = 0.56) or low HDL (p for trend = 0.12).

Table 7 lists the adjusted associations of concentrations of selected congeners with the prevalence of metabolic syndrome. We found significant trends for associations with metabolic syndrome for 1,2,3,7,8-PeCDD, 1,2,3,6,7,8-HxCDD, 1,2,3,4,6,7,8-HpCDD, OCDD, CDF, 2,3,4,7,8-PeCDF, PCB-126, PCB-105, PCB-114, PCB-118, PCB-123, and PCB-167. The highest quartiles of PCB-126 and PCB-105 had adjusted ORs of 95%-CI of 9.1–4.1 and 7.3–3.4, respectively, compared with the respective referents.

### Table 2. Prevalence of metabolic syndrome and its five components in the participants (%).

| Metabolic Component | Both sexes (n=1,374) | Male (n=627) | Female (n=747) |
|---------------------|---------------------|-------------|-------------|
| Metabolic syndrome  |                     |             |             |
| Yes                 | 11.6                | 16.7        | 7.4         |
| No                  | 87.0                | 81.5        | 91.6        |
| Unknown             | 1.4                 | 1.8         | 1.1         |
| Components†         |                     |             |             |
| BMI ≥ 25 kg/m²      |                     |             |             |
| Yes                 | 23.7                | 32.4        | 16.5        |
| No                  | 73.5                | 66.2        | 82.9        |
| Unknown             | 1.0                 | 1.4         | 0.7         |
| Blood pressure ≥ 130/85 mmHg or a history of physician-diagnosed hypertension | | |
| Yes                 | 41.3                | 50.4        | 33.7        |
| No                  | 58.6                | 49.6        | 66.1        |
| Unknown             | 0.1                 | 0.0         | 0.1         |
| Triglycerides ≥ 150 mg/dl |                     |             |             |
| Yes                 | 16.2                | 26.3        | 7.8         |
| No                  | 83.5                | 73.4        | 92.0        |
| Unknown             | 0.3                 | 0.3         | 0.3         |
| HDL cholesterol < 40 mg/dl in men or 50 mg/dl in women | | |
| Yes                 | 10.3                | 10.4        | 10.3        |
| No                  | 89.4                | 89.3        | 89.4        |
| Unknown             | 0.3                 | 0.3         | 0.3         |

Table 3. Concentrations and TEQs for PCDD, PCDF, and DL-PCB congener in the blood of the subjects.

| Congener | Concentration [pg/g lipid; median (25%–75%)] | TEF† | TEQ [pg TEQ/g lipid; median (25%–75%)] |
|----------|-----------------------------------------------|------|----------------------------------------|
| PCDDs    |                                              |      |                                        |
| 2,3,7,8-TCDD | 1.0 (0.0–2.0) | 1    | 1.0 (0.0–2.0) |
| 1,2,3,7,8-PeCDD | 5.0 (0.0–7.0) | 1    | 7.0 (0.0–7.0) |
| 1,2,3,4,7,8-HxCDD | 0.0 (0.0–3.0) | 0.1  | 0.0 (0.0–3.0) |
| 1,2,3,6,7,8-HxCDD | 15 (0.0–21) | 0.1  | 1.5 (0.0–21) |
| 1,2,3,8,9-HxCDD | 3.0 (0.0–4.0) | 0.1  | 3.0 (0.0–4.0) |
| 1,2,3,4,6,7,8-HpCDD | 12 (0.0–18) | 0.01 | 12 (0.0–18) |
| OCDD     | 140 (89–230) | 0.0001 | 0.01 (0.0–0.02) |
| Total PCDDs | 7.4 (4.6–11.2) |      |                                        |
| PCDFs    |                                              |      |                                        |
| 2,3,7,8-TCDF | 1.0 (0.0–2.0) | 0.1  | 1.0 (0.0–2.0) |
| 1,2,3,7,8-PeCDF | 0.0 (0.0–0.0) | 0.05 | 0.0 (0.0–0.0) |
| 1,2,3,4,7,8-HxCDF | 7.0 (0.0–11.0) | 0.5  | 3.5 (0.5–5.5) |
| 1,2,3,6,7,8-HxCDF | 3.0 (0.0–4.0) | 0.1  | 0.3 (0.0–0.4) |
| 1,2,3,5,6,7,8-HxCDF | 3.0 (0.0–5.0) | 0.1  | 0.3 (0.0–0.5) |
| 1,2,3,4,6,7,8-HpCDD | 0.0 (0.0–0.0) | 0.0  | 0.0 (0.0–0.0) |
| 1,2,3,4,6,7,8-HpCDF | 2.0 (0.0–3.0) | 0.01 | 0.0 (0.0–0.0) |
| OCDF     | 0.0 (0.0–0.0) | 0.0001 | 0.0 (0.0–0.0) |
| Total PCDFs | 4.5 (2.9–6.8) |      |                                        |
| Total PCDDs/PCDFs | 12 (7.7–18) |      |                                        |
| PCBs     |                                              |      |                                        |
| PCB-77   | 0.0 (0.0–0.0) | 0.0001 | 0.0 (0.0–0.0) |
| PCB-81   | 0.0 (0.0–0.0) | 0.0001 | 0.0 (0.0–0.0) |
| PCB-126  | 40 (22–78) | 0.1  | 4.0 (2.2–7.8) |
| PCB-169  | 30 (20–60) | 0.01 | 0.3 (0.20–0.50) |
| Non-ortho PCBs |                     |      |                                        |
| PCB-105  | 1.300 (750–2,400) | 0.0001 | 0.13 (0.08–0.24) |
| PCB-114  | 460 (250–830) | 0.0005 | 0.23 (0.13–0.42) |
| PCB-118  | 7.500 (4,200–13,000) | 0.0001 | 0.75 (0.42–1.3) |
| PCB-123  | 100 (60–200) | 0.0001 | 0.01 (0.01–0.02) |
| PCB-156  | 2.800 (1,500–4,800) | 0.0005 | 1.4 (0.75–2.4) |
| PCB-157  | 770 (420–1,300) | 0.0003 | 0.39 (0.21–0.65) |
| PCB-167  | 1.300 (730–2,300) | 0.0001 | 0.01 (0.01–0.02) |
| PCB-189  | 320 (180–380) | 0.0001 | 0.03 (0.02–0.06) |
| Mono-ortho PCBs |                     |      |                                        |
| Total DL-PCBs | 3.0 (1.6–5.1) |      |                                        |
| Total TEQs | 7.6 (4.4–13) |      |                                        |
| Median (25%–75%)] TEF | 5.3 (2.3–13) compared with the referent. | Data from Van den Berg et al. (1998). |

†We diagnosed metabolic syndrome as the presence of three or more of these five components.
Discussion

Several studies of veterans exposed to high levels of dioxins have suggested that one of the plausible diseases associated with dioxins is type 2 diabetes (Henriksen et al. 1997; Michalek et al. 1999). This association is supported by similar epidemiologic studies in subjects exposed to high levels of dioxins in Seveso, Italy (Pesarini et al. 2003), and Korean Vietnam veterans exposed to Agent Orange (Kim et al. 2003). However, a causal association of dioxins or other POPs with diabetes is far from established. Recently, low levels of exposure to dioxins were reported to be associated with increased risk of diabetes (Lee et al. 2006), and additionally with increased risk of metabolic syndrome (Lee et al. 2007), in the U.S. population in the 1999–2002 NHANES. Metabolic syndrome has been increasing in Asian countries, including Japan, with the Westernization of lifestyle. We studied whether associations similar to those found in the U.S. population exist among the Japanese population. Lee et al. (2007) investigated the associations between some POPs and metabolic syndrome among nondiabetic subjects. However, excluding diabetic subjects could result in a sample less representative of general inhabitants. Therefore, in the present study we examined the associations both including and excluding the diabetic subjects.

We found that all of the TEQs of PCDDs, PCDFs, and DL-PCBs and total TEQs had significant nonadjusted and adjusted associations with the prevalence of metabolic syndrome. The highest quartile of total TEQs had a high adjusted OR of 5.3. Analyses of each component of metabolic syndrome indicated that all of the TEQs of PCDDs, PCDFs, and DL-PCBs and total TEQs were associated with high blood pressure and elevated triglycerides. The TEQs of PCDDs and DL-PCBs and total TEQs showed significant trends for associations with high HbA1c. In particular, the highest quartiles of DL-PCB TEQs and total TEQs had high adjusted ORs of 8.0 and 8.6, respectively, in the prevalence of high HbA1c. Also, the DL-PCB TEQs and total TEQs were associated with all five components of metabolic syndrome, and the ORs in the highest quartile of the TEQ of DL-PCBs in four of the five components were higher than those for PCDDs or PCDFs. From these findings, of the five components of metabolic syndrome, high blood pressure, elevated triglycerides, and glucose intolerance may be most closely associated with these pollutants, particularly with DL-PCBs. In contrast, high BMI was not associated with TEQs except for DL-PCBs. Of the five components, high BMI might be the least associated with exposure to these pollutants.

TEQ-based analyses can be justified if the aryl hydrocarbon (Ah) receptor is the mechanism involved. PCDDs/PCDFs and DL-PCBs that have been assigned a TEF are known to exhibit various biological and toxic actions through binding with Ah receptors, so we conducted the TEQ-based analyses. However, Lee et al. (2007) recently reported that the background exposure to some POPs may be closely related to metabolic syndrome, with different POPs related to different metabolic syndrome traits. To examine whether Ah-receptor–mediated mechanisms of the examined pollutants are critical in their link to metabolic syndrome, we further analyzed the associations of the concentration of each congener separately with the prevalence of metabolic syndrome. We found that 12 of the selected 16 congeners, widely distributed among PCDDs, PCDFs, and DL-PCBs, had trends for association with metabolic syndrome. In particular, the highest quartiles of PCB-126 and PCB-105 had adjusted ORs of

Table 4. Nonadjusted and adjusted associations of the TEQs of PCDDs, PCDFs, DL-PCBs and total TEQs with the prevalence of metabolic syndrome.

| TEQs | No. of subjects | No. of cases | Nonadjusted | Adjusted* |
|------|----------------|-------------|-------------|-----------|
|      |                |             |             |           |
| PCDDs |               |             |             |           |
| < 4.60 | 343            | 15          | Referent     | Referent   |
| ≥ 4.60 to < 7.39 | 344            | 39          | 2.8 (1.5–4.5) | 2.2 (1.2–4.4) |
| ≥ 7.39 to < 11.20 | 339            | 38          | 2.7 (1.5–5.2) | 2.1 (1.1–4.3) |
| ≥ 11.20 | 348            | 68          | 5.4 (3.1–10)  | 3.2 (1.6–6.7) |
| p for trend | < 0.01         | < 0.01      |             |           |
| PCDFs |               |             |             |           |
| < 2.90 | 330            | 9           | Referent     | Referent   |
| ≥ 2.90 to < 4.50 | 347            | 40          | 4.6 (2.3–10)  | 4.0 (1.9–9.3) |
| ≥ 4.50 to < 6.80 | 352            | 48          | 5.6 (2.9–12)  | 4.1 (1.9–9.7) |
| ≥ 6.80 | 345            | 63          | 8.0 (4.1–17)  | 4.4 (2.0–11) |
| p for trend | < 0.01         | 0.04        |             |           |
| DL-PCBs |              |             |             |           |
| < 4.40 | 339            | 14          | Referent     | Referent   |
| ≥ 4.40 to < 7.60 | 339            | 27          | 2.0 (1.1–4.1) | 1.9 (0.95–4.0) |
| ≥ 7.60 to < 13.00 | 325            | 39          | 3.2 (1.7–6.2) | 2.8 (1.3–6.2) |
| ≥ 13.00 | 371            | 80          | 6.4 (3.6–12)  | 4.8 (2.2–11) |
| p for trend | < 0.01         | < 0.01      |             |           |
| Total TEQs |            |             |             |           |
| < 12.00 | 303            | 10          | Referent     | Referent   |
| ≥ 12.00 to < 20.00 | 363            | 29          | 2.6 (1.3–5.6) | 2.3 (1.1–5.3) |
| ≥ 20.00 to < 31.00 | 353            | 47          | 4.5 (2.3–9.7) | 3.7 (1.7–8.7) |
| ≥ 31.00 | 355            | 74          | 7.7 (4.1–16)  | 5.3 (2.3–13) |
| p for trend | < 0.01         | < 0.01      |             |           |

*Adjusted for age, sex, smoking habit, drinking habit, regional block, residential area, and survey year (model df = 19).

Table 5. Nonadjusted and adjusted associations of the TEQs of PCDDs, PCDFs, DL-PCBs and total TEQs with the prevalence of metabolic syndrome, excluding the subjects with prevalent diabetes.

| TEQs | No. of subjects | No. of cases | Nonadjusted | Adjusted* |
|------|----------------|-------------|-------------|-----------|
|      |                |             |             |           |
| PCDDs |               |             |             |           |
| < 4.49 | 325            | 12          | Referent     | Referent   |
| ≥ 4.49 to < 7.27 | 329            | 31          | 2.7 (1.4–5.6) | 2.2 (1.1–4.8) |
| ≥ 7.27 to < 11.00 | 311            | 28          | 2.6 (1.3–5.3) | 2.1 (0.99–4.7) |
| ≥ 11.00 | 344            | 51          | 4.6 (2.5–9.2) | 3.4 (1.6–7.8) |
| p for trend | < 0.01         | < 0.01      |             |           |
| PCDFs |               |             |             |           |
| < 2.83 | 326            | 9           | Referent     | Referent   |
| ≥ 2.83 to < 4.40 | 326            | 31          | 3.7 (1.8–8.3) | 3.5 (1.6–8.2) |
| ≥ 4.40 to < 6.60 | 323            | 37          | 4.5 (2.2–10)  | 3.8 (1.7–9.2) |
| ≥ 6.60 | 334            | 45          | 5.5 (2.8–12)  | 3.8 (1.6–9.7) |
| p for trend | < 0.01         | 0.07        |             |           |
| DL-PCBs |              |             |             |           |
| < 4.28 | 327            | 9           | Referent     | Referent   |
| ≥ 4.28 to < 7.40 | 320            | 24          | 2.9 (1.4–6.7) | 3.1 (1.4–7.4) |
| ≥ 7.40 to < 12.87 | 334            | 35          | 4.2 (2.1–9.4) | 5.0 (2.1–13) |
| ≥ 12.87 | 328            | 54          | 6.9 (3.5–15)  | 7.3 (2.9–20) |
| p for trend | < 0.01         | < 0.01      |             |           |
| Total TEQs |            |             |             |           |
| < 12.00 | 303            | 10          | Referent     | Referent   |
| ≥ 12.00 to < 19.00 | 318            | 22          | 2.2 (1.0–4.9) | 2.2 (0.98–5.0) |
| ≥ 19.00 to < 30.00 | 345            | 35          | 3.3 (1.7–7.2) | 3.2 (1.4–7.6) |
| ≥ 30.00 | 343            | 55          | 5.6 (2.9–12)  | 5.1 (2.1–13) |
| p for trend | < 0.01         | < 0.01      |             |           |

*Adjusted for age, sex, smoking habit, drinking habit, regional block, residential area, and survey year (model df = 19).
9.1 and 7.3, respectively, a finding consistent with that of the TEQ-based analyses.

We found associations of PCDD and PCDF TEQs with the prevalence of metabolic syndrome; in contrast, Lee et al. (2007) found no such associations. These associations in our TEQ-based analyses agreed with the results of our congener-specific analyses. Lee et al. (2007) also reported that the risk of metabolic syndrome was highest in the third quartile and then plateaued in the case of DL-PCBs, whereas we found a significant trend for the association between the TEQ of DL-PCBs and metabolic syndrome. This association in our study persisted or strengthened when diabetic subjects were excluded from the analyses. Although we could not clearly explain this discrepancy between the findings of Lee et al. (2007) and ours, the difference in prevalence of metabolic syndrome (24.3% and 9.3%, respectively, when excluding diabetic subjects) might influence this discrepancy.

The associations observed in this cross-sectional study should be carefully interpreted regarding cause–effect relations. For diabetic subjects, slower elimination of dioxins was not supported in a study on Vietnam veterans (Michalek et al. 2003), in which no difference in TCDD half-life was reported between diabetic and non diabetic subjects.

### Table 6. Adjusted ORs (95% CIs) of the prevalence of each component of metabolic syndrome by quartiles of the TEQs of PCDDs, PCDFs, and DL-PCBs and total TEQs (quartile 1 is the referent).

| Component | Quartile 2 | Quartile 3 | Quartile 4 | p for trend |
|-----------|-----------|-----------|-----------|------------|
| BMI ≥ 25 kg/m² | | | | |
| PCDDs | 1.5 (0.97–2.3) | 1.5 (0.83–2.3) | 1.5 (0.91–2.4) | 0.30 |
| PCDFs | 1.3 (0.85–2.0) | 1.5 (0.97–2.4) | 1.3 (0.79–2.2) | 0.56 |
| DL-PCBs | 1.7 (1.1–2.6) | 1.8 (1.1–3.0) | 2.6 (1.5–4.7) | < 0.01 |
| Total TEQs | 1.3 (0.86–2.1) | 1.9 (1.2–3.1) | 1.9 (1.1–3.3) | 0.07 |
| Blood pressure ≥ 130/85 mmHg or a history of physician-diagnosed hypertension | | | | |
| PCDDs | 0.93 (0.68–1.4) | 1.0 (0.70–1.6) | 1.6 (1.0–2.5) | 0.01 |
| PCDFs | 1.3 (0.92–2.0) | 1.6 (1.1–2.4) | 1.9 (1.2–3.0) | < 0.01 |
| DL-PCBs | 1.0 (0.71–1.6) | 1.8 (1.0–3.7) | 1.9 (1.1–3.1) | < 0.01 |
| Total TEQs | 1.3 (0.86–1.9) | 1.2 (0.81–1.9) | 1.9 (1.1–3.1) | 0.01 |
| Triglycerides ≥ 150 mg/dL | | | | |
| PCDDs | 2.1 (1.3–3.5) | 2.1 (1.2–3.7) | 2.7 (1.5–4.8) | < 0.01 |
| PCDFs | 1.5 (0.87–2.5) | 2.1 (1.2–3.6) | 2.2 (1.2–4.1) | 0.02 |
| DL-PCBs | 2.4 (1.4–4.3) | 3.4 (1.8–6.6) | 5.2 (2.6–11) | < 0.01 |
| Total TEQs | 1.2 (1.1–3.5) | 3.0 (1.6–5.6) | 3.8 (1.9–7.5) | 0.01 |
| HDL cholesterol < 40 mg/dL in males or 50 mg/dL in females | | | | |
| PCDDs | 1.8 (0.83–3.4) | 3.2 (1.7–6.4) | < 0.01 |
| PCDFs | 1.5 (0.85–2.8) | 2.0 (1.0–3.7) | 1.9 (0.98–4.0) | 0.12 |
| DL-PCBs | 1.1 (0.58–1.9) | 1.9 (0.98–3.8) | 2.1 (0.98–4.5) | 0.06 |
| Total TEQs | 1.3 (0.72–2.5) | 1.9 (0.97–3.8) | 2.7 (1.3–5.9) | < 0.01 |
| HbA1c ≥ 5.6% or a history of physician-diagnosed diabetes | | | | |
| PCDDs | 2.7 (1.2–6.6) | 3.5 (1.6–8.7) | 4.6 (2.0–12) | < 0.01 |
| PCDFs | 2.1 (0.93–5.2) | 3.9 (1.5–9.6) | 3.2 (1.3–8.3) | 0.08 |
| DL-PCBs | 2.1 (0.90–5.3) | 3.1 (1.2–8.0) | 8.0 (2.2–22) | < 0.01 |
| Total TEQs | 3.3 (1.3–10) | 4.5 (1.7–14) | 8.6 (3.1–28) | < 0.01 |

Adjusted for age, sex, smoking habit, drinking habit, regional block, residential area, and survey year (model df = 19).

### Table 7. Adjusted ORs (95% CIs) of the prevalence of metabolic syndrome by quartiles of the concentrations of the selected congeners (Q1 = referent).

| Congener | Quartile 2 | Quartile 3 | Quartile 4 | p for trend |
|----------|-----------|-----------|-----------|------------|
| PCDDs | 1.23,7,8-PeCDD | 2.8 (1.2–8.4) | 2.0 (0.77–6.4) | 3.7 (1.4–12) | 0.04 |
| 12,3,6,7,8-HxCDD | 2.5 (1.3–6.6) | 3.0 (1.4–6.7) | 3.6 (1.7–8.2) | < 0.01 |
| 12,3,4,6,7,8-HpCDD | 2.1 (1.1–3.8) | 3.0 (1.7–5.5) | 4.5 (2.4–8.8) | < 0.01 |
| ODCD | 1.9 (1.1–3.5) | 3.0 (1.7–5.5) | 3.7 (2.0–6.9) | < 0.01 |
| PCDFs | 2.3,4,7,8-PeCDF | 3.8 (1.7–9.8) | 4.1 (1.8–11) | 5.3 (2.2–14) | < 0.01 |
| 1,2,3,6,7,8-HxCDF | 1.2 (0.40–3.7) | 2.9 (1.3–7.9) | 2.8 (1.2–8.0) | 0.06 |
| PCBs | PB-126 | 2.5 (1.1–5.6) | 4.9 (2.4–11) | 9.1 (4.1–21) | < 0.01 |
| PB-169 | 1.7 (0.78–4.2) | 1.7 (0.79–4.2) | 1.4 (0.60–3.7) | 0.73 |
| PB-105 | 1.9 (0.87–4.3) | 4.6 (2.3–9.9) | 7.3 (3.4–17) | < 0.01 |
| PB-114 | 3.1 (1.5–7.1) | 3.6 (1.6–8.7) | 6.4 (2.7–17) | < 0.01 |
| PB-118 | 2.5 (1.3–6.3) | 3.8 (1.8–8.3) | 6.5 (3.0–15) | < 0.01 |
| PB-123 | 1.3 (0.90–3.7) | 3.4 (1.7–9.6) | 5.9 (2.8–13) | < 0.01 |
| PB-156 | 1.5 (0.76–3.2) | 1.7 (0.78–3.7) | 2.0 (0.84–4.9) | 0.23 |
| PB-157 | 1.3 (0.65–2.5) | 1.1 (0.51–2.3) | 1.2 (0.54–2.8) | 0.81 |
| PB-167 | 2.3 (1.1–4.8) | 2.7 (1.3–6.1) | 4.1 (1.8–9.7) | < 0.01 |
| PB-189 | 0.69 (0.34–1.4) | 1.1 (0.54–2.3) | 0.98 (0.42–2.3) | 0.79 |

Adjusted for age, sex, smoking habit, drinking habit, regional block, residential area, and survey year (model df = 19).
and glucose intolerance may be closely associ-
ated with the blood levels of these pollutants,
especially with DL-PCBs. Basic studies in
animals and further epidemiologic studies
using longitudinal designs should be further
directed to define the mechanism and the
causality between exposure to these pollutants
and metabolic syndrome.

REFERENCES

Blanck HM, Marcus M, Hertzberg V, Tolbert PE, Rubin C,
Henderson AK, et al. 2000. Determinants of polychlorinated
biphenyl serum decay among women in the Michigan PBB
cohort. Environ Health Perspect 108:147–152.

Flegal KM, Carroll MD, Ogden CL, Johnson CL. 2002. Prevalence
and trends in obesity among US adults, 1999–2000. JAMA
288:1723–1727.

Flesh-Jamys D, Becher H, Gurn P, Jung D, Konietzko J,
Manz A, et al. 1996. Elimination of polychlorinated dibenzo-
p-dioxins and dibenzo-furans in occupationally exposed persons. J Toxcol
Environ Health 47:363–378.

Ford ES. 2005. Prevalence of the metabolic syndrome defined
by the International Diabetes Federation among adults in
the U.S. Diabetes Care 28:2745–2749.

Fujiyoshi PT, Michalek JE, Matsuzira F. 2006. Molecular epi-
demiologic evidence for dibatogenic effects of dioxin
exposure in U.S. Air Force veterans of the Vietnam War.
Environ Health Perspect 114:1677–1683.

Henriksen GL, Ketchum NS, Michalek JE. 1997. Serum
Dioxin and diabetes mellitus in veterans of
Operation Ranch Hand. Epidemiology 8:252–258.

Kim JS, Lim HS, Cho SI, Cheong HK, Lim MK. 2003. Impact of
Agent Orange exposure among Korean Vietnam veterans.
Ind Health 41:149–157.

Ko GT, Cockram CS, Chou CC, Yeung V, Chan WB, So WW, et al.
2005. High prevalence of metabolic syndrome in Hong
Kong Chinese—comparison of three diagnostic criteria.
Diabetes Res Clin Pract 69:160–168.

Konishi Y, Kuwabara K, Hori S. 2001. Continuous surveillance
of organochlorine compounds in human breast milk from
1972 to 1998 in Osaka, Japan. Arch Environ Contam Toxicol
40:571–576.

Lakka HM, Lakkaonen DE, Lakka TA, Niskanen LK, Kumpusalo E,
Tuomilehto J, et al. 2002. The metabolic syndrome and total
and cardiovascular disease mortality in middle-aged men.
JAMA 288:2709–2716.

Lee DH, Lee IK, Porta M, Steffes M, Jacobs DR Jr. 2007.
Relationship between serum concentrations of persistent
organic pollutants and the prevalence of metabolic syn-
drome among non-diabetic adults: results from the National
Health and Nutrition Examination Survey 1999–2002.
Diabetologia 50:1841–1851.

Lee DH, Lee IK, Song K, Steffes M, Toscano W, Baker BA, et al.
2006. A strong dose–response relation between serum
concentrations of persistent organic pollutants and dia-
betes: results from the National Health and Examination
Survey 1999–2002. Diabetes Care 29:1638–1644.

Lindström J, Hooper K, Petreas M, Stephens R, Gilman A. 1995.
Workshop on perinatal exposure to dioxin-like compounds.
V. Summary. Environ Health Perspect 103(suppl 2):135–142.

Lorenz C, Okoloise M, Williams K, Stern MP, Haffner SM. 2003.
The metabolic syndrome as predictor of type 2 diabetes:
the San Antonio Heart Study. Diabetes Care 26:3153–3159.

Malki S, Wong ND, Franklin SS, Kamath TV, C’Haiten GJ, Pio Jr,
et al. 2004. Impact of the metabolic syndrome on mortality
from coronary heart disease, cardiovascular disease, and all
causes in United States adults. Circulation 110:1245–1250.

McNeill AM, Rosamond WD, Gorman CJ, Golden SH, Schmidt MI,
East HE, et al. 2005. The metabolic syndrome and 11-year risk
of incident cardiovascular disease in the atherosclerosis risk
in communities study. Diabetes Care 28:385–390.

Michalek JE, Akhtar FZ, Kiel JL. 1999. Serum dioxin, insulin,
fasting glucose, and sex hormone-binding globulin in
veterans of Operation Ranch Hand. J Clin Endocrinol Metab
84:1540–1543.

Michalek JE, Ketchum NS, Tripathi RC. 2003. Diabetes melli-
tus and 2,3,7,8-tetrachlorodibenzo-p-dioxin elimination in
veterans of Operation Ranch Hand. J Toxicol Environ Health
A 66:211–221.

Ministry of the Environment, Government of Japan. 2004.
Dioxins and Furans Inventory. [in Japanese]. Tokyo:Ministry of
the Environment, Government of Japan.

Nakamura T, Nakai K, Matsuzira T, Suzuki S, Saito Y, Sato H.
2008. Determination of dioxins and polychlorinated biphenyls
in breast milk, maternal blood and cord blood from residents
of Tohoku, Japan. Sci Total Environ 394:35–61.

Nakanishi N, Suzuki K, Tatara K. 2003. Clustered features of the
metabolic syndrome and the risk for increased aortic pulse
wave velocity in middle-aged Japanese men. Angiology
NCEP ATP-III (National Cholesterol Education Program).
2002. Third report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) final report. Circulation
106:3143–3421. Available: http://circ.ahajournals.org/cgi/
reprint/106/25/3143 [accessed 23 February 2009].

Pesatori AC, Consonni D, Bachetti S, Zocchetti C, Bonzini M,
Baccarelli A, et al. 2003. Short- and long-term morbidity
and mortality in the population exposed to dioxin after the
“Seveso Accident”. Ind Health 41:127–138.

Porta M. 2006. Persistent organic pollutants and the burden of
diabetes. Lancet 368:558–559.

Rohlfing CL, Little RR, Widdmeyer HM, England JD, Madsen R,
Harris MI, et al. 2000. Use of GHb (HbA1c) in screening for
undiagnosed diabetes in the US population. Diabetes Care
23:187–191.

Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DSJ,
Haffner SM, et al. 2003. Metabolic syndrome with and
without C-reactive protein as a predictor of coronary heart
disease and diabetes in the West of Scotland Coronary
Prevention Study. Circulation 108:414–419.

Tan CE, Ma S, Wai D, Chew SK, Tai ES. 2004. Can we apply the
National Cholesterol Education Program Adult Treatment
Panel definition of the metabolic syndrome to Asians?
Diabetes Care 27:1182–1186.

Uemura H, Arisaka K, Iyoshi M, Satoh S, Sumiyoshi Y,
Morimaga K, et al. 2008. Associations of environmental
exposure to dioxin with prevalent diabetes among general
inhabitants in Japan. Environ Res 108:63–68.

Van den Berg M, Birnbaum LS, Boxveld AT, Brunstrom B,
Cook P, Feeley M, et al. 1998. Toxic equivalency factors
(TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife.
Environ Health Perspect 106:775–782.

Weisglas-Kuperus N. 1998. Neurodevelopmental, immuno-
logical, and endocrinological indices of perinatal human exposure
to PCBs and dioxins. Chemosphere 37:1845–1853.

Wittsiepe J, Schrey P, Ewers U, Selenka F, Wilhelm M. 2000.
Decrease of PCDD/F levels in human blood from Germany over
the past ten years (1989–1998). Chemosphere 40:1103–1109.